DOCSLIB.ORG

5.09 Pyrans and Their Benzo Derivatives: Applications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
5.09 Pyrans and Their Benzo Derivatives: Applications 5.09 Pyrans and their Benzo Derivatives: Applications GRAHAM R. GEEN, JOHN M. EVANS and ANTONIO K. VONG SmithKline Beecham Pharmaceuticals, Harlow, UK 5.09.1 PHARMACEUTICALS 470 5.09.1.1 Antibiotics and Antiinfectives 470 5.09.1.1.1 Macrolide antibiotics 470 5.09.1.1.2 Aminoglycosides 472 5.09.1.1.3 Anthracycline antibiotics 473 5.09.1.1.4 Miscellaneous antibiotics 473 5.09.1.2 Cardiovascular Agents 474 5.09.1.3 Neurological Modulators 477 5.09.1.4 Antiallergic and Antiasthmatic Agents 477 5.09.1.5 Antiinftammatory Agents 478 5.09.1.6 Reproduction and Genitourinary Agents 479 5.09.1.7 Growth Promoters 479 5.09.1.8 Antidiabetic Agents 480 5.09.1.9 Miscellaneous 481 5.09.1.10 Healthcare 481 5.09.2 VETERINARY PRODUCTS 482 5.09.2.1 Antibiotics and Antiinfectives 483 5.09.2.2 Antiinflammatory Agents 483 5.09.3 AGROCHEMICALS 485 5.09.4 TOXINS 485 5.09.4.1 Marine Toxins 486 5.09.4.2 Terrestrial Toxins 487 5.09.5 POLYMERS AND ADDITIVES 488 5.09.5.1 Polymers 488 5.09.5.1.1 Natural polymers 488 5.09.5.1.2 Hydrogels 489 5.09.5.1.3 Glycopolymers 489 5.09.5.1.4 Photoactive polymers 490 5.09.5.1.5 Photosensitizers andphotoinitiators 490 5.09.5.2 Surfactants 491 5.09.6 FOOD PRODUCTS 492 5.09.7 DYES AND PIGMENTS 493 5.09.7.1 Fluorescent Dyes and Brighteners 493 5.09.7.2 Laser Dyes 494 5.09.7.3 Color Formers 494 5.09.7.4 Photochromism 495 5.09.7.5 Infrared Absorbing Dyes 496 5.09.7.6 Natural Dyes 496 5.09.8 USE IN CHEMICAL SYNTHESIS 496 469 470 Pyrans and their Benzo Derivatives: Applications 5.09.9 CYCLODEXTRINS 498 5.09.9.1 Pharmaceuticals 499 5.09.9.2 Agrochemicals 499 5.09.9.3 Flavors and Fragrances 499 5.09.9.4 Reprographics and Phototechnological Applications 500 5.09.1 PHARMACEUTICALS A large number of pharmaceutical agents containing the pyran unit that have been encountered in a survey of the literature, including patent applications and granted patents. A selection is thus required of the more pertinent for inclusion in this part of the chapter. Compounds that have reached the healthcare market in at least one country form the major part of this section and are joined by those compounds that await registration, or that have been registered, as they are likely to be launched in the near future. The inclusion of compounds that are currently in clinical trials has been restricted to those that are in the final phase. Such trials include administration to patients suffering from the disease targeted for the compound. Having passed to this stage of what is becoming an ever more rigorous process, compounds in this class are highly likely to be launched. However, no distinction is made between the different classes considered, as apart from post-launch, their status is not entirely clear. The pharmaceutical agents that contain the pyran ring are arranged by therapeutic area (disease state), and in each area they are grouped by structure and phar- macological mechanism of action. 5.09.1.1 Antibiotics and Antiinfectives 5.09.1.1.1 Macrolide antibiotics The macrolide antibiotics are part of a large and diverse class of natural products isolated from the culture broths of certain soil microorganisms. The fermentation-derived macrolides are classified by the ring size of the aglycone, the basic lactone ring system, to which are appended either or both amino and neutral sugar residues. The predominant subclasses are based on a 14- or 16-membered aglycone. Reviews have covered the 14-membered- <B-93MI 509-0l> and 16-membered aglycones <B- 94MI 509-01). The archetypal 14-membered aglycone antibiotic, erythromicin (1), isolated from Sac- charopolyspora erythraea, is the most widely used member of the macrolide class <57JA6070), being prescribed for the treatment of respiratory tract, skin and soft tissue infections, particularly in cases of penicillin allergy. However, erythromycin can cause intestinal discomfort, and its instability in the acidic environment of the stomach leads to unsatisfactory pharmacokinetics. Certain intramolecular reactions involving degradation of the aglycone occur in this environment that lead to inactive products, and in an effort to counter this tendency and to improve the palatability, a number of semisynthetic analogues has been developed. Roxithromycin (2) <81FRP2473525>, azithromycin (3) <84EUP101186>, clarithromycin (4) <84JAN187>, flurithromycin (5) <83JAN1439>, dirithromycin (6) <90JANl27l>, and erythromycin carbonate (7) <89EUP307l77> were designed to foil undesired trans- formation of the aglycone nucleus, while erythromycin acistrate (8) is a prodrug formulated as the stearate addition salt <88MI 509-01). Other salt derivatives of erythromycin are in development. The 16-membered macrolides comprise two main families, the tylosins and the leucomycins, that are based on the substitution patterns of their aglycone units. While the former class has not as yet produced any compounds for human use, the latter has provided several drugs. Thus, josamycin (9) has been isolated from Streptomyces narbonensis <67JAN174>, and midecamycin (10) from Strep- tomyces mycarofaciens <71JAN319>. Miokamycin, diacetylated midecamycin (11) <76JAN536>, and rokitamycin (12) <81JAN1OO1> are two semisynthetic analogues that have been prepared to improve absorption and palatability. Although studies into the mechanism of action of the macrolides have concentrated on erythro- mycin, it is considered that they all possess the ability to penetrate the cell, bind to the 50S ribosomal subunit and disrupt protein synthesis. Amphotericin B (13), first approved for use in 1958, remains the primary systemically administered fungicidal compound used today. Toxicity is a major side effect, and many complexes and for- mulations have been evaluated in an effort to reduce it while retaining the antifungal potency. One Pyrans and their Benzo Derivatives: Applications 471 NMe2 o OH (1) A = C=0, R1 = H, R2 = OH 1 2 (2) A = C=NOCH2O(CH2)2OMe, R = H, R = OH 1 2 (3) A = N(Me)CH2, R = H, R = OH (4) A = C=O, R1 = H, R2 = OMe (5) A = C=0, R1 = H, R2 = F (8) A = C=0, R1 = Ac, R2 = H; stearate salt OR4 CHO (9) R1 = COBu\ R2 = R4 = H, R3 = Ac (10) R1 = R3 = COEt, R2 = R4 = H (11) R1 = R3 = COEt, R2 = R4 = Ac (12) R1 = COPrn, R2 = COEt, R3 = R4 = H formulation that is reported to offer this advantageous profile is the 1:1 complex of amphotericin B with cholesteryl sulfate <91MI 509-01 >. The compound exerts its pharmacological effect by binding to ergosterol, which is commonly found in fungal cell membranes, thus leading to membrane instability and breakdown. CO2H 472 Pyrans and their Benzo Derivatives: Applications Extraction of the mycelia oi Streptomyces tsukubaensis <87JAN1249> produces the novel macrolide immunosuppressant agent tacrolimus (14). It is particularly useful in combination with cortico- steroids following liver or kidney transplantations, and is beneficial in countering graft rejection. MeO. MeO,, o (14) 5.09.1.1.2 Aminoglycosides Another important class of antibiotic agents is the aminocyclitol aminoglycosides exemplified by the gentamicin C complex (15) <63USP3O91572>, a Gram-negative bactericide. Like the macrolide antibiotics they are thought to act directly on the ribosome (but at the 30S unit) and thus to inhibit protein synthesis. Other closely related compounds isolated from natural sources are sisomicin (16; R = H) from Micromonospora inyoesis <70JAN551>, micronomicin (17) from Micronospora sagamiensis <74JAN793>, astromicin (18) from Micromonospora olivoasterospora <77JAN552>, and the furanose ribostamycin (19) from Streptomyces ribosidificus <7OJAN173>. Semisynthetic analogues, designed to improve the spectrum of antibiotic activity, are netilimicin (16; R = Et) <76CC206> derived from sisomicin, dibekacin (20) <71JAN485>, isepamicin (21) <75GEP(O)2437159>, and arbekacin (22) <80BEP879925>. NHMe HO NH2 H,N NHR MeO (18) R'HN NHR5 NHR4 (17) R1 = Ac, R2-R5 = H, R6 = Me (20) R!-R« = H 4 2 3 5 6 (21) R>-R = H R = R = OH, R = (S)-COCH(OH)CH2NH2, R = Me 4 6 5 (22) R'-R , R = H, R = (S)-COCH(OH)(CH2)2NH2 Pyrans and their Benzo Derivatives: Applications 473 5.09.1.1.3 Anthracycline antibiotics The members of the class of naturally occurring anthracycline antibiotics derived from anthra- quinone that are reviewed here have been isolated from culture broths of Streptomyces species. They have a particular application as antitumor agents and exert their pharmacological activity by blocking the synthesis of RNA copies of DNA at the cellular level by binding to DNA. Daunorubicin (23) <64NAT706> and doxorubicin (24) <69MI 509-0l>, are both produced by culturing Streptomyces peucitus. The latter is active against a whole range of cancers and has been one of the most widely used chemotherapeutic agents for human tumors. However two of the drawbacks of these agents are their level of cardiotoxicity and incidence of alopecia (hair loss). In order to improve the therapeutic ratio further natural analogues have been sought and aclarubicin (25), isolated from Streptomyces galileus <75JAN830>, is particularly useful against some forms of lung cancer, with a lower incidence of side effects. Beside the search for natural analogues with improved side effect profile, several semisynthetic analogues such as zorubicin (26) <74GEP(O)23272ll>, pirarubicin (27) <79JAN1O82>, and idarubicin (28) <76Mi 509-01 > have been prepared. An interesting synthetic analogue is epirubicin (29) where the stereochemistry of the 4'-hydroxyl group in the sugar residue is inverted <75JMC703>. The mode of antitumor action and efficacy of the compound class are retained in this compound while the cardiotoxicity is reduced. CO,Me "OH "OH NH2 (23) R1 = OMe, R2 = Ac, R3 = OH 1 2 3 (24) R = OMe, R = COCH2OH, R = OH (26) R'= OMe, R2 = C(Me)=NHCOPh, R3 = OH 2 3 (27) R'= OMe, R = COCH2OH, R = OTHP (28) R1 = H, R2 = Ac, R3 = OH 1 2 3 (29) R = OMe, R = COCH2OH, R = epi-OU Undue levels of toxicity precluded the progression of the natural anthracycline nogalamycin (30), but a semisynthetic derivative menogaril (31) was used to overcome this problem <77JAN628>.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0264810 A1 Lin Et Al
    US 20120264810A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0264810 A1 Lin et al. (43) Pub. Date: Oct. 18, 2012 (54) COMPOSITIONS AND METHODS FOR 61/400,763, filed on Jul. 30, 2010, provisional appli ENHANCING CELLULARUPTAKE AND cation No. 61/400,758, filed on Jul. 30, 2010. INTRACELLULAR DELVERY OF LIPID PARTICLES Publication Classification (75) Inventors: Paulo J.C. Lin, Vancouver (CA); (51) Int. Cl. Yuen Yic. Tam, Vancouver (CA); C07. 4I/00 (2006.01) Srinivasulu Masuna, Edmonton A6II 47/24 (2006.01) (CA); Marco A. Ciufolini, CI2N 5/071 (2010.01) Vancouver (CA); Michel Roberge, A63L/73 (2006.01) Vancouver (CA); Pieter R. Cullis, A6II 47/22 (2006.01) Vancouver (CA) C07D 215/46 (2006.01) A 6LX 3L/705 (2006.01) (73) Assignee: The University of British (52) U.S. Cl. ............ 514/44A: 540/5: 546/163; 514/788: Columbia, Vancouver (CA) 514/44 R; 435/375 (21) Appl. No.: 13/497,395 (57) ABSTRACT (22) PCT Filed: Sep. 22, 2010 Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are describedIn particu (86). PCT No.: PCT/B2O1O/OO2518 lar embodiments, the methods of the invention include con tacting a cell with a lipid particle and a compound that binds S371 (c)(1), a Na+/K+ ATPase to enhance uptake of the lipid particle b\the (2), (4) Date: Jul. 3, 2012 cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound Related U.S. Application Data that enhances uptake of the lipid particles b\ the cell The (60) Provisional application No.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.1] European Commission
    MTC eHealth DSI [eHDSI v2.2.1] European Commission - Master Translation/Transcoding Catalogue Responsible : eHDSI Solution Provider PublishDate : Thu Jun 01 17:03:48 CEST 2017 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73
    [Show full text]
  • X-Ray Microscope Röntgenstrahlmikroskop Microscope À Rayons X
    (19) TZZ ___T (11) EP 2 511 844 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G06F 21/00 (2013.01) G21K 7/00 (2006.01) 12.08.2015 Bulletin 2015/33 (21) Application number: 12164870.3 (22) Date of filing: 10.10.2007 (54) X-ray microscope Röntgenstrahlmikroskop Microscope à rayons X (84) Designated Contracting States: • Stewart, Jeffrey, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Harris, Michael, N. SI SK TR Los Alamos, NM 87544 (US) • Burrell, Anthony, K. (30) Priority: 10.10.2006 US 850594 P Los Alamos, NM 87544 (US) (43) Date of publication of application: (74) Representative: Lorente Berges, Ana 17.10.2012 Bulletin 2012/42 A2 Estudio Legal C/ Hermosilla Nº 59, bajo izq (62) Document number(s) of the earlier application(s) in 28001 Madrid (ES) accordance with Art. 76 EPC: 07874491.9 / 2 084 519 (56) References cited: WO-A1-97/25614 US-A1- 2003 023 562 (73) Proprietor: XRpro Sciences, Inc. US-A1- 2004 128 518 US-A1- 2004 235 059 Los Alamos, NM 87544 (US) US-A1- 2005 015 596 (72) Inventors: • POTTS PHILIP J ET AL: "Atomic spectrometry • Birnbaum, Eva, R. update__X-ray fluorescence spectrometry", Los Alamos, NM 87544 (US) JOURNAL OF ANALYTICAL ATOMIC • Koppisch, Andrew, T. SPECTROMETRY, ROYAL SOCIETY OF Los Alamos, NM 87544 (US) CHEMISTRY, vol. 21, no.
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]